Publication
Title
Interleukin-15 and interleukin-15 receptor α mRNA-engineered dendritic cells as promising candidates for dendritic cell-based vaccination in cancer immunotherapy
Author
Abstract
Dendritic cell (DC)-based tumor vaccination holds great potential and is intensively being studied in cancer immunotherapy. Although DC vaccination can result in a survival advantage as shown in various cancer types, there is still room for improvement. Therefore, current DC vaccines urge rigorous optimization in order to increase their immune stimulating capacities for induction of antitumor immunity. In this context, strategies where the interleukin (IL) 15 transpresentation mechanism is incorporated, appear to be of great value due to the activating potential of IL-15 towards IL-15Rβγ expressing cells, such as cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells. In the past 5 years, our research group designed different strategies to generate IL-15-expressing DC with superior T cell and NK cell-activating properties. In this review, we briefly describe the design of our latest DC vaccine, in which DC are genetically engineered to transpresent IL-15 via mRNA electroporation and discuss the capacity of this newly designed DC vaccine to activate NK cells and CTLs. Overall, IL-15 transpresenting DC show the potential to activate antitumor immunity and are promising candidates for DC based cancer immunotherapy.
Language
English
Source (journal)
Journal of cancer science & therapy
Publication
2016
Volume/pages
8:1(2016), p. 15-19
Full text (Publishers DOI)
Full text (open access)
UAntwerpen
Faculty/Department
Research group
Publication type
Subject
Affiliation
Publications with a UAntwerp address
External links
Record
Identification
Creation 16.06.2016
Last edited 17.06.2016
To cite this reference